Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Active Hyper-IgD Syndrome (HIDS)
NCT01303380Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2011
- Primary completion
- Jul 2014
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of canakinumab in Hyperimmunoglobulinemia D with periodic fever syndrome (HIDS), sponsored by Novartis. Started Mar 2011; status: completed.
02
Drugs
canakinumab
03
Conditions
Hyperimmunoglobulinemia D with periodic fever syndrome (HIDS)
Beyond the preview
Go deeper on NCT01303380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01303380.